Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.

ABSTRACT:

Background

Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored treatments, which are currently being tested in clinical trials. CUPISCO (NCT03498521) was a phase II randomized study of targeted therapy/cancer immunotherapy versus platinum-based chemotherapy in patients with previously untreated, unfavorable CUP, defined as per the European Society for Medical Oncology guidelines. We present a preliminary, descriptive molecular analysis of 464 patients with stringently diagnosed, unfavorable CUP enrolled in the CUPISCO study.

Materials and methods

Genomic profiling was carried out on formalin-fixed, paraffin-embedded tissue to detect genomic alterations and assess tumor m

SUBMITTER: Westphalen CB 

PROVIDER: S-EPMC10774891 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature